Start free

Arcutis Biotherapeutics, Inc. (ARQT) insider trading

Recent insider transactions reported to the SEC on Form 4 — directors and officers buying or selling their own company’s stock. Sourced directly from public SEC filings, latest filed Nov 18, 2026.

Filings shown
37
Open-market buys
0
Open-market sells
31

Counts cover the 37 most recent Form 4 filings Tradune holds for ARQT (filed May 5 – Nov 18, 2026); the score below covers only the trailing 90 days (0 buys, 11 sells). SEC EDGAR Form 4 filings for ARQT last checked Nov 21, 2026, 09:00 UTC; the latest ARQT filing Tradune holds was filed Nov 18, 2026. This is not guaranteed to be the complete record — see ARQT's full Form 4 filing history on SEC EDGAR.

Open-market activity, last 90 days

Purchases (Form 4 code P) and sales (code S) on the 12 filings Tradune holds for ARQT filed Aug 24 – Nov 18, 2026. Grants, exercises, tax withholding and the other Form 4 transaction codes are left out.

12 open-market sales by Rule 10b5-1 checkbox

On filings with the 10b5-1 box checked
7 sales· 69,068 sh
checkbox disclosed
On filings with the box not checked
5 sales· 44,592 sh
not proof that no plan exists
Not comparable
0 sales· 0 sh
filed before Apr 1, 2023, or no checkbox value in the filing data

Counts are Form 4 lines as filed. The checkbox is one per filing, so every sale on a filing with the box checked is counted there even if only some of its transactions were under a plan; it records what the filer disclosed, and the three categories are not a judgement about why a sale was made.

Open-market purchases and sales by insider
Insider Buys Sells Shares bought Shares sold Value
Masaru MatsudaEVP, Chief Legal Officer 0 4 — 54,882 −$1,753,353
Terrie CurranDirector 0 3 — 39,272 −$984,035
Howard G. WelgusDirector 0 3 — 14,186 −$374,837
Todd WatanabeOfficer (see filing) 0 1 — 4,377 −$139,466
Patrick BurnettEVP, Chief Medical Officer 0 1 — 943 −$30,047

Value = shares × the price reported on each Form 4 (+ purchases, − sales); every open-market line in this window disclosed a price.

Insider-activity score

0/ 100

Net insider sales
0 distinct buyers0 buy · 11 sell tx

Summarises ~90 days of public SEC Form 4 activity — more distinct buyers, officer involvement and net buying score higher. A description of filing activity, not a rating or buy signal. How this score is computed →

Get alerted when insiders buy the stocks you own

Add your holdings — no brokerage login — and Insider Radar sends a Telegram alert when an open-market Form 4 buy of $100,000 or more is filed on a stock you hold or watch.

Free for everyone right now · no card · nothing to buy

Start free

How to read this: an open-market purchase (Form 4 code P) is a buy at the market price with the insider’s own money, as opposed to a grant, award or option exercise; an open-market sale is code S. When two or more distinct insiders report open-market purchases in the same 90-day window, this site labels that a cluster — a definition, not a forecast; see insider cluster buying. “Held after” is Form 4 Table I column 5; “Change” = shares ÷ holdings before the trade (held after − shares for an acquisition, held after + shares for a disposition).

Insider Buying at ARQT

No open-market insider purchases (Form 4 code P) were reported for ARQT between May 5, 2026 and Nov 18, 2026. The filings below may include other transaction types — sales, grants, option exercises, and tax withholding — shown for completeness; they are not open-market purchases.

Recent Form 4 filings

Source: SEC EDGAR Form 4 · transaction codes explained

Howard G. Welgus Director · filed Nov 18, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise 822 $6.52 36,029 +2.3% Nov 16, 2026
Option exercise 1,018 $7.51 37,047 +2.8% Nov 16, 2026
Option exercise 2,254 $8.63 39,301 +6.1% Nov 16, 2026
Open-market sale 10b5-1 box checked 4,728 $28.16 34,573 −12% Nov 16, 2026
Option exercise Stock Option (right to buy) 822 — — — Nov 16, 2026
Option exercise Stock Option (right to buy) 1,018 — — — Nov 16, 2026
Option exercise Stock Option (right to buy) 2,254 — — — Nov 16, 2026

† change in this filer’s own reported holding line (Form 4 Table I, col. 5), not of total company ownership; small prior holdings produce large percentages, so under 100 shares the prior holding is shown instead.

“10b5-1 box checked” = the filer checked the Form 4 box stating that a transaction on the filing was made under a plan intended to satisfy Rule 10b5-1(c); “10b5-1 box not checked” = the box was left blank, which does not prove that no plan exists. The box applies to Form 4s filed from April 1, 2023; older filings, and boxes we could not read, carry no tag. What the 10b5-1 box means.

Todd Watanabe Officer (see filing) · filed Nov 17, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Gift 144,232 — 568,594 −20% Nov 13, 2026
Masaru Matsuda EVP, Chief Legal Officer · filed Nov 4, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise Stock Option (right to buy) 40,000 — — — Nov 4, 2026
Option exercise 40,000 $3.64 151,289 +36% Nov 4, 2026
Open-market sale 10b5-1 box checked 40,000 $34.32 111,289 −26% Nov 4, 2026
Open-market sale 10b5-1 box checked 1,219 $31.86 111,289 −1.1% Nov 2, 2026
Patrick Burnett EVP, Chief Medical Officer · filed Nov 4, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 943 $31.86 116,649 −0.8% Nov 2, 2026
Todd Watanabe Officer (see filing) · filed Nov 4, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 4,377 $31.86 712,826 −0.6% Nov 2, 2026
Robert A. Scott Director · filed Oct 28, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award 2,819 — 2,819 — Oct 23, 2026
Grant / award Stock Option (right to buy) 20,507 — — — Oct 23, 2026
Grant / award Stock Option (right to buy) 8,663 — — — Oct 23, 2026
Howard G. Welgus Director · filed Oct 19, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise 822 $6.52 36,663 +2.3% Oct 15, 2026
Option exercise 1,018 $7.51 37,681 +2.8% Oct 15, 2026
Option exercise 2,254 $8.63 39,935 +6.0% Oct 15, 2026
Open-market sale 10b5-1 box checked 4,728 $26.93 35,207 −12% Oct 15, 2026
Option exercise Stock Option (right to buy) 822 — — — Oct 15, 2026
Option exercise Stock Option (right to buy) 1,018 — — — Oct 15, 2026
Option exercise Stock Option (right to buy) 2,254 — — — Oct 15, 2026
Masaru Matsuda Officer (see filing) · filed Sep 18, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 3,674 $25.00 112,508 −3.2% Sep 16, 2026
Howard G. Welgus Director · filed Sep 17, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise 822 $6.52 37,297 +2.3% Sep 15, 2026
Option exercise 1,019 $7.51 38,316 +2.7% Sep 15, 2026
Option exercise 2,255 $8.63 40,571 +5.9% Sep 15, 2026
Open-market sale 10b5-1 box checked 4,730 $24.18 35,841 −12% Sep 15, 2026
Option exercise Stock Option (right to buy) 822 — — — Sep 15, 2026
Option exercise Stock Option (right to buy) 1,019 — — — Sep 15, 2026
Option exercise Stock Option (right to buy) 2,255 — — — Sep 15, 2026
Masaru Matsuda Officer (see filing) · filed Sep 10, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 9,989 $25.03 116,182 −7.9% Sep 8, 2026
Terrie Curran Director · filed Aug 28, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise 11,148 $7.51 34,674 +47% Aug 27, 2026
Open-market sale 10b5-1 box not checked 11,148 $25.03 23,526 −32% Aug 27, 2026
Option exercise 27,052 $8.63 50,578 +115% Aug 27, 2026
Open-market sale 10b5-1 box not checked 27,052 $25.03 23,526 −53% Aug 27, 2026
Option exercise Stock Option (right to buy) 11,148 — — — Aug 27, 2026
Option exercise Stock Option (right to buy) 27,052 — — — Aug 27, 2026
Terrie Curran Director · filed Aug 24, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise 1,072 $7.51 24,598 +4.6% Aug 20, 2026
Open-market sale 10b5-1 box not checked 1,072 $26.04 23,526 −4.4% Aug 20, 2026
Option exercise Stock Option (right to buy) 1,072 — — — Aug 20, 2026
Patrick Burnett Officer (see filing) · filed Aug 21, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 1,697 $27.00 117,592 −1.4% Aug 19, 2026
Howard G. Welgus Director · filed Aug 19, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise 822 $6.52 37,931 +2.2% Aug 17, 2026
Option exercise 1,019 $7.51 38,950 +2.7% Aug 17, 2026
Option exercise 2,255 $8.63 41,205 +5.8% Aug 17, 2026
Open-market sale 10b5-1 box checked 4,730 $26.18 36,475 −11% Aug 17, 2026
Option exercise Stock Option (right to buy) 822 — — — Aug 17, 2026
Option exercise Stock Option (right to buy) 1,019 — — — Aug 17, 2026
Option exercise Stock Option (right to buy) 2,255 — — — Aug 17, 2026
Patrick Burnett Officer (see filing) · filed Aug 13, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise 6,700 $3.64 125,989 +5.6% Aug 12, 2026
Open-market sale 10b5-1 box not checked 6,700 $26.08 119,289 −5.3% Aug 12, 2026
Option exercise Stock Option (right to buy) 6,700 — — — Aug 12, 2026
Option exercise 8,300 $3.64 127,589 +7.0% Aug 11, 2026
Open-market sale 10b5-1 box not checked 8,300 $26.52 119,289 −6.5% Aug 11, 2026
Option exercise Stock Option (right to buy) 8,300 — — — Aug 11, 2026
Patrick Burnett Officer (see filing) · filed Aug 5, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 955 $26.12 119,289 −0.8% Aug 3, 2026
Masaru Matsuda Officer (see filing) · filed Aug 5, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 1,230 $26.12 126,171 −1.0% Aug 3, 2026
Todd Watanabe Officer (see filing) · filed Aug 5, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 4,375 $26.12 717,203 −0.6% Aug 3, 2026
Christopher Peetz Director · filed Jul 17, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award 4,315 — 4,315 — Jul 15, 2026
Grant / award Stock Option (right to buy) 21,486 — — — Jul 15, 2026
Grant / award Stock Option (right to buy) 13,010 — — — Jul 15, 2026
Howard G. Welgus Director · filed Jul 17, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise 822 $6.52 38,565 +2.2% Jul 15, 2026
Option exercise 1,019 $7.51 39,584 +2.6% Jul 15, 2026
Option exercise 2,255 $8.63 41,839 +5.7% Jul 15, 2026
Open-market sale 10b5-1 box checked 4,730 $26.91 37,109 −11% Jul 15, 2026
Option exercise Stock Option (right to buy) 822 — — — Jul 15, 2026
Option exercise Stock Option (right to buy) 1,019 — — — Jul 15, 2026
Option exercise Stock Option (right to buy) 2,255 — — — Jul 15, 2026
Howard G. Welgus Director · filed Jun 17, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 635 $25.67 37,743 −1.7% Jun 17, 2026
Option exercise 822 $6.52 39,200 +2.1% Jun 15, 2026
Option exercise 1,019 $7.51 40,219 +2.6% Jun 15, 2026
Option exercise 2,255 $8.63 42,474 +5.6% Jun 15, 2026
Open-market sale 10b5-1 box checked 4,096 $24.41 38,378 −9.6% Jun 15, 2026
Option exercise Stock Option (right to buy) 822 — — — Jun 15, 2026
Option exercise Stock Option (right to buy) 1,019 — — — Jun 15, 2026
Option exercise Stock Option (right to buy) 2,255 — — — Jun 15, 2026
Sue-Jean Lin Director · filed Jun 17, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 4,946 $24.38 27,567 −15% Jun 15, 2026
Patrick J. Heron Director · filed Jun 9, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award 5,778 — 32,213 +22% Jun 5, 2026
Grant / award Stock Option (right to buy) 16,667 — — — Jun 5, 2026
Sue-Jean Lin Director · filed Jun 9, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award 5,778 — 32,513 +22% Jun 5, 2026
Grant / award Stock Option (right to buy) 16,667 — — — Jun 5, 2026
Howard G. Welgus Director · filed Jun 9, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award 5,778 — 38,378 +18% Jun 5, 2026
Grant / award Stock Option (right to buy) 16,667 — — — Jun 5, 2026

Listing the 25 most recent of 37 Form 4 filings held for ARQT; the 12 older filings (filed May 5 – Jun 9, 2026) are counted above but not listed here — see ARQT's full Form 4 filing history on SEC EDGAR.

Insider filings reported around the same time

Other companies whose most recent Form 4 was filed closest to ARQT's (Nov 18, 2026).

Frequently asked about ARQT insider activity

How many insiders bought ARQT stock in these Form 4 filings?

No open-market purchases (Form 4 code P) of ARQT shares were reported by Arcutis Biotherapeutics, Inc. insiders between May 5, 2026 and Nov 18, 2026. The 37 filings shown on this page cover other transaction types — sales, grants, option exercises, and tax withholding.

Who filed the most recent Form 4 for ARQT?

The most recent Form 4 on this page was filed by Howard G. Welgus (Director) on Nov 18, 2026, reporting 7 transactions. The original document is linked from the filing list above on SEC EDGAR. Amended filings (Form 4/A) may later revise reported figures.

What was the largest open-market ARQT insider sale shown?

The largest open-market sale among the filings shown was 40,000 ARQT shares at $34.32 (about $1,372,672) by Masaru Matsuda (EVP, Chief Legal Officer) on Nov 4, 2026. Value is shares × the price reported on the Form 4; that Form 4 has the Rule 10b5-1 box checked.

New to Form 4s? The transaction codes, the 90-day window and the 0–100 score are defined on the insider-activity score methodology page.

Get insider alerts for ARQT — and your whole portfolio

Tradune watches SEC Form 4 filings and flags insider-cluster buying across everything you hold, routed to you automatically. Free for everyone right now · no card · nothing to buy

This score summarizes SEC Form 4 filing activity over the trailing 90 days. It is descriptive, not predictive — not a rating, recommendation, or investment advice. Data: SEC EDGAR (public domain), as filed; amendments may revise figures. Tradune is not a registered investment adviser.

Data as filed; amended filings (Form 4/A) may revise figures. Sales may occur under prearranged Rule 10b5-1 trading plans.